Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis

Abstract

Background and Objective

The presence of lipid-specific immunoglobulin M bands in the cerebrospinal fluid (CSF) predicts an aggressive course in patients with relapsing–remitting multiple sclerosis (MS) during early stages of the disease. This study examined whether it is also a predictor of long-term prognosis in MS.

Methods

Eighty-one patients with MS and 22 headache controls were analyzed for anti-lipid IgM reactivity in CSF samples. The correlation between the presence of lipid-specific immunoglobulin M bands in CSF and disease progression was assessed in patients with MS who had been followed longitudinally for, on average, more than 11 years.

Results

Lipid-specific immunoglobulin M bands were detected in the CSF of 24 of 81 patients with MS and were absent in the CSF of all headache controls. Median time to conversion to a secondary progressive course was 11 years in patients with bands and 22 years in patients without bands. Median time to an Expanded Disability Status Scale score of 4 was 14 years in patients with bands and 24 years in patients without bands.

Conclusion

The presence of lipid-specific immunoglobulin M bands in CSF predicts a more adverse long-term outcome in patients with MS; it may thus define a subset of patients who might benefit from aggressive treatment during the early phase of the disease.

Keywords

biological markers cerebrospinal fluid immunoglobulin M multiple sclerosis prognosis survival analysis

Get full access to this article

View all access options for this article.

References

1 Lucchinetti C Brück W Parisi J Scheithauer B Rodriguez M Lassmann H . Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707–717.

2 Bielekova B Kadom N Fisher E . MRI as a marker for disease heterogeneity in multiple sclerosis. Neurology 2005; 65: 1071–1076.

3 Noseworthy JH Lucchinetti C Rodriguez M Weinshenker BG . Multiple sclerosis. N Engl J Med 2000; 343: 938–952.

4 Ebers GC . Natural history of multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 71(Suppl. 2): ii16–ii19.

5 Bielekova B Martin R . Development of biomarkers in multiple sclerosis. Brain 2004; 127: 1463–1478.

6 Rudick RA French CA Breton D Williams GW . Relative diagnostic value of cerebrospinal fluid kappa chains in MS: comparison with other immunoglobulin tests. Neurology 1989; 39: 964–968.

7 Rinker JR Trinkaus K Cross AH . Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis. Neurology 2006; 67: 1288–1290.

8 Izquierdo G Angulo S Garcia-Moreno JM . Intrathecal IgG synthesis: marker of progression in multiple sclerosis patients. Acta Neurol Scand 2002; 105: 158–163.

9 Avasarala JR Cross AH Trotter JL . Oligoclonal band number as a marker for prognosis in multiple sclerosis. Arch Neurol 2001; 58: 2044–2045.

10.

10 Villar LM Sádaba MC Roldán E . Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 2005; 115: 187–194.

11.

11 McDonald WI Compston A Edan G . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121–127.

12.

12 Roxburgh RH Seaman SR Masterman T . Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144–1151.

13.

13 Villar LM García-Barragán N Espiño M . Influence of oligoclonal IgM specificity in multiple sclerosis disease course. Mult Scler 2008; 14: 183–187.

14.

14 Lublin FD Reingold SC . Defining the clinical course of multiple sclerosis: results of an international survey: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907–911.

15.

15 Kurtzke JF . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452.

16.

16 Sharief MK Thompson EJ . The predictive value of intrathecal immunoglobulin synthesis and magnetic resonance imaging in acute isolated syndromes for subsequent development of multiple sclerosis. Ann Neurol 1991; 29: 147–151.

17.

17 Villar LM Masjuan J González-Porqué P . Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology 2002; 59: 555–559.

18.

18 Perini P Ranzato F Calabrese M Battistin L Gallo P . Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis. J Neurol Neurosurg Psychiatry 2006; 77: 953–955.

19.

19 Berland R Wortis HH . Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol 2002; 20: 253–300.

20.

20 Lennon VA Wingerchuk DM Kryzer TJ . A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106–2112.